NCT00720447Unknown2 期
Phase II Study of Low Intensity Allogeneic Transplantation in Mantle Cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 25
- 主要终点
- Progression-free survival
研究概览
简要总结
RATIONALE: Giving chemotherapy and monoclonal antibody therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
PURPOSE: This phase II trial is studying donor stem cell transplant in treating patients with mantle cell lymphoma.
详细描述
OBJECTIVES:
Primary
- Determine progression-free survival in patients with mantle cell lymphoma undergoing low-intensity allogeneic stem cell transplantation.
Secondary
- Determine overall survival of these patients.
- Determine the toxicity by way of adverse event profile of this regimen in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Progression-free survival
次要结局
- Overall survival
- Toxicity
研究者
相似试验
已完成
2 期
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerChronic Myeloproliferative DisordersMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsLymphomaLeukemiaNCT00806767Institut Paoli-Calmettes82
已完成
2 期
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and MelphalanGraft Versus Host DiseaseLymphomaLeukemiaNCT00577278City of Hope Medical Center41
Unknown
不适用
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic AnemiaChronic Myeloproliferative DisordersKidney CancerMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsLymphomaLeukemiaNCT00295997University of California, San Francisco35
已完成
2 期
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaLymphomaLeukemiaNCT01027000Alliance for Clinical Trials in Oncology68
Unknown
2 期
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin LymphomaLymphomaNCT00908180Cancer Research UK47